Abstract
Approximately 60% of cancer incidence and 70% of cancer mortality occurs in individuals older than 65 years. The optimal approach to cancer therapy in older adults is often unclear. Historically, advanced age has been an exclusion criterion in clinical cancer trials, and older adults have been consistently underrepresented. As a result, there is a lack of information about treatment efficacy and tolerability in this population.
Comprehensive Geriatric Assessment (CGA) is one of the most useful tools for the oncologist to make decisions related to older patients diagnosed with cancer. This tool has proved to be very useful to detect many deficits, tolerance to chemotherapy and survival in such patients. In this review, we analyze the role of CGA in decision making in geriatric oncology.
Keywords: Cancer, chemotherapy, cognitive status, comorbidity, comprehensive geriatric assessment, depression, frailty, functional status, geriatric syndromes, instrumental activities of daily live, making decisions, multidisciplinary assessment, older, quality of life, vulnerability.
Anti-Cancer Agents in Medicinal Chemistry
Title:Tools For Decision-Making In Older Cancer Patients. Role Of The Comprehensive Geriatric Assessment
Volume: 14 Issue: 5
Author(s): M.J. Molina-Garrido, C. Guillen-Ponce, C. Sanchez Castellano, B. Montero Errasquin, A. Mora-Rufete and A.J. Cruz-Jentoft
Affiliation:
Keywords: Cancer, chemotherapy, cognitive status, comorbidity, comprehensive geriatric assessment, depression, frailty, functional status, geriatric syndromes, instrumental activities of daily live, making decisions, multidisciplinary assessment, older, quality of life, vulnerability.
Abstract: Approximately 60% of cancer incidence and 70% of cancer mortality occurs in individuals older than 65 years. The optimal approach to cancer therapy in older adults is often unclear. Historically, advanced age has been an exclusion criterion in clinical cancer trials, and older adults have been consistently underrepresented. As a result, there is a lack of information about treatment efficacy and tolerability in this population.
Comprehensive Geriatric Assessment (CGA) is one of the most useful tools for the oncologist to make decisions related to older patients diagnosed with cancer. This tool has proved to be very useful to detect many deficits, tolerance to chemotherapy and survival in such patients. In this review, we analyze the role of CGA in decision making in geriatric oncology.
Export Options
About this article
Cite this article as:
Molina-Garrido M.J., Guillen-Ponce C., Castellano Sanchez C., Errasquin Montero B., Mora-Rufete A. and Cruz-Jentoft A.J., Tools For Decision-Making In Older Cancer Patients. Role Of The Comprehensive Geriatric Assessment, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (5) . https://dx.doi.org/10.2174/1871520614999140416143258
DOI https://dx.doi.org/10.2174/1871520614999140416143258 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Heparanase as a Target in Cancer Therapy
Current Cancer Drug Targets Nutrition Support of Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Current Nutrition & Food Science Bioactive N-Phenylimidazole Derivatives
Current Chemical Biology Patents in miRNAs Biomarkers for Gastrointestinal Cancer Diagnostics
Recent Patents on Biomarkers Long Term Prognosis in IgG4-Related Systemic Disease (ISD)
Current Immunology Reviews (Discontinued) Editorial [Hot Topic: Molecular Targeted Therapy of Gastrointestinal Cancer (Guest Editor: Marcus W. Wiedmann)]
Current Cancer Drug Targets Biomedical Applications of Accelerator Mass Spectrometry
Current Analytical Chemistry Efficacy and Safety of the Combination of Docetaxel (Taxotere®) with Targeted Therapies in the Treatment of Solid Malignancies
Current Drug Targets Thyroid Hormone Treatment for Differentiated Thyroid Carcinoma: What Drug, How Long, What Dose?
Current Cancer Therapy Reviews Inhibition of Epithelial-mesenchymal Transition in Response to Treatment with Metformin and Y27632 in Breast Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Epigenetic Modifications in Acute Lymphoblastic Leukemia: From Cellular Mechanisms to Therapeutics
Current Gene Therapy CRISPR/Cas9 Genome Editing Tool: A Promising Tool for Therapeutic Applications on Respiratory Diseases
Current Gene Therapy Oxidative Stress and Neurodegenerative Diseases: A Review of Upstream and Downstream Antioxidant Therapeutic Options
Current Neuropharmacology Cyclodextrin-based Polymeric Nanoparticles as Efficient Carriers for Anticancer Drugs
Current Pharmaceutical Biotechnology Lack of Association between miR-605 rs2043556 Polymorphism and Overall Cancer Risk: A Meta-analysis of Case-control Studies
MicroRNA Meet Our Editor:
Current Enzyme Inhibition Role of ABC Transporters in Veterinary Medicine: Pharmaco- Toxicological Implications
Current Medicinal Chemistry Counter-Regulatory Role of Bile Acid Activated Receptors in Immunity and Inflammation
Current Molecular Medicine Current Development of Metal Complexes with Diamine Ligands as Potential Anticancer Agents
Current Medicinal Chemistry Unconventional Players on the Striated Muscle Field: microRNAs, Signaling Pathways and Epigenetic Regulators
Current Stem Cell Research & Therapy